Hormonal
GLP-1RAs are associated with rare but serious adverse events including acute pancreatitis, gallbladder disease, and potential worsening of diabetic retinopathy, though causal relationships for some (like thyroid cancer) are not confirmed in humans.
Be aware of rare but serious side effects like pancreatitis, gallbladder disease, and worsening of diabetic retinopathy (especially if you have pre-existing eye disease). While the risk of thyroid cancer is a concern in animal studies, no human cases have been confirmed. Report any severe abdominal pain or vision changes to your doctor.
Rare but serious adverse events have been reported. Acute pancreatitis and elevated pancreatic enzymes are infrequent, and meta-analyses generally show no significant increase in pancreatitis or pancreatic cancer risk. Similarly, concerns regarding medullary thyroid cancer (MTC) stem primarily from preclinical findings; no confirmed human cases have been documented... GLP-1RAs are also associated with an increased risk of gallbladder and biliary disease, particularly in high-dose weight-loss trials, and semaglutide has been linked to worsening diabetic retinopathy in patients with pre-existing disease, possibly due to rapid HbA1c reductions.
Why this rating
Based on pharmacovigilance databases and meta-analyses cited in the bibliometric review.
Source
Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis
Riad Mohammed Abdelrahman et al. · INQUIRY The Journal of Health Care Organization Provision and Financing · 2026
DOI 10.1177/00469580261441498
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) cause frequent, dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation, reflux) that typically diminish over time but are a major cause of treatment discontinuation.Good
- GLP-1RAs are associated with an increased risk of hypoglycemia, particularly when combined with insulin or sulfonylureas, although the risk remains lower than with those agents alone.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →